This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (105)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Flow Cytometric Nuclear DNA Ploidy Analysis

B. T. Montgomery, MD; Ofer Nativ, MD; Michael L. Blute, MD; George M. Farrow, MD; Robert P. Myers, MD; Horst Zincke, MD; Terry M. Therneau, PhD; Michael M. Lieber, MD

Arch Surg. 1990;125(3):327-331.

Abstract
• Over a 16-year period (1966 to 1981), 349 patients underwent radical retropubic prostatectomy for pathologic stage B adenocarcinoma of the prostate. Nuclear DNA content was measured by flow cytometry on available archival material of 283 patients. Two hundred sixty-one patients (92%) had high-quality histograms. The ploidy distribution was as follows: DNA diploid, 177 (68%); DNA tetraploid, 74 (28%); and DNA aneuploid, 10(4%) The average follow-up was 9.4 years. At the time of follow-up, 53 patients (20%) within the study group had developed tumor progression: 22 local, 23 systemic, and 8 both. The ploidy distribution of the population that developed tumor progression was 27 DNA diploid (51%), 16 DNA tetraploid (30%), and 10 DNA aneuploid (19%). This ploidy distribution is significantly different from that found for the nonprogression group with stage B disease. Overall, 31% of patients with DNA nondiploid tumors had tumors that progressed compared with 15% of patients with DNA diploid tumors. All (100%) DNA aneuploid tumors progressed. The DNA ploidy distribution of all pathologic stage B prostate cancers differs significantly from that found in more advanced stages (C and D1) previously reported for the same time interval. However, the ploidy distribution of stage B tumors that progressed closely resembles that of the stage C and D1 tumors. These results further support the working hypothesis that nuclear DNA content has marked prognostic significance for patients with adenocarcinoma of the prostate. It seems to us that analysis of ploidy by flow or static cytometry will become an essential tool for treating patients with localized prostate cancer.

(Arch Surg. 1990;125:327-331)

Author Affiliations
From the Departments of Urology (Drs Montgomery, Nativ, Blute, Myers, Zincke, Therneau, and Lieber), Pathology (Dr Farrow), and Oncology (Dr Therneau), Mayo Clinic, Rochester, Minn.

Footnotes
Accepted for publication November 10, 1989.

Read before the annual meeting of the Society of Surgical Oncology, San Francisco, Calif, May 25, 1989.

Reprint requests to Department of Urology, Mayo Clinic, Rochester, MN 55905 (Dr Lieber).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer
Ross et al.
Clin. Cancer Res. 2003;9:6357-6362.
ABSTRACT | FULL TEXT  

Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610
Pollack et al.
JCO 2003;21:1238-1248.
ABSTRACT | FULL TEXT  

Detection of Early Prostate Cancer: Serendipitous or Systematic?
Iczkowski et al.
JAMA 1998;279:1439-1441.
FULL TEXT